Targeted Antibiotic Delivery System with Enhanced Efficacy

A nanoparticle-based antibiotic delivery system that enhances efficacy through targeted delivery, improved stability, and controlled release.

The growing antibiotic resistance of harmful microbes has led to a pressing need for innovative drug delivery methods. The original patent's approach of using aqueous polyacrylate nanoparticle emulsions has limitations in terms of targeted delivery, stability, and controlled release. This new inventive concept addresses these limitations by introducing modified surface chemistry, pH-sensitive polymers, and controlled release profiles to optimize antibiotic treatment.

The new system comprises nanoparticles with modified surface chemistry to enhance retention at the site of infection, thereby increasing antibiotic efficacy. The nanoparticles are coated with a biocompatible polymer and have a size range of 10-50 nm, resulting in improved bioavailability and reduced toxicity. A pH-sensitive polymer is incorporated to reduce antibiotic degradation over time. The controlled release profile is regulated by the concentration of a pH-sensitive additive, allowing for tailored release rates. The nanoparticles are designed to respond to changes in the local microenvironment, such as pH or temperature, to optimize antibiotic release.

The new claims introduce novel elements such as targeted delivery, pH-sensitive polymers, and controlled release profiles, which are not present in the original patent. These innovations provide a significant improvement over the existing approach, making the new inventive concept non-obvious and novel.

Alternative embodiments may include varying the type of biocompatible polymer, adjusting the size range of the nanoparticles, or incorporating different pH-sensitive additives. Variations could also include using different antibiotics or targeting different types of infections.

The targeted antibiotic delivery system has significant commercial potential in the pharmaceutical industry, particularly in the treatment of antibiotic-resistant infections. The system's improved efficacy and reduced toxicity make it an attractive solution for hospitals, clinics, and patients worldwide.